The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

Zacks Equity Research shares Kratos Defense & Security Solutions KTOS as the Bull of the Day and GSK PLC GSK as the Bear of ...

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

In early UK corporate news, GSK announced a buyback and upped its 2031 sales target. Here is what you need to know at the London market open: FTSE 100: called down 0.3% at 8,542.57 Hang Seng: down 1.0 ...

ShareThe year 2024 etched an indelible mark on Nigeria’s economic history as over 20 highprofile multinational corporations, including Unilever Nigeria Plc, Procter & Gamble, GlaxoSmithKline Consumer ...

The company’s biggest industry partnership has been with the drug giant GlaxoSmithKline (GSK) in London, which led to the discovery of drug candidates, including a cancer drug now in trials.

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.